Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer

被引：6
|
作者：
Ogino, Misato [1 ,2 ,3 ]
Fujii, Takaaki [1 ,2 ]
Koibuchi, Yukio [3 ]
Nakazawa, Yuko [1 ,2 ]
Takata, Daisuke [3 ]
Shirabe, Ken [2 ]
机构：
[1] Gunma Univ, Div Breast & Endocrine Surg, Gunma, Japan
[2] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Gunma, Japan
[3] Natl Hosp Org, Dept Breast & Endocrine Surg, Takasaki Gen Med Ctr, Gunma, Japan
来源：
ANTICANCER RESEARCH | 2021年 / 41卷 / 08期
关键词：
nab-PTX; HER-2 positive breast cancer; cyclophosphamide; neoadjuvant chemotherapy; PATHOLOGICAL COMPLETE RESPONSE; ALBUMIN-BOUND PACLITAXEL; LONG-TERM OUTCOMES; TRIAL; 5-FLUOROURACIL/EPIRUBICIN/CYCLOPHOSPHAMIDE; COMBINATION; DOCETAXEL; SURVIVAL; REGIMENS; THERAPY;
D O I：
10.21873/anticanres.15185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: This phase II trial evaluated the efficacy and safety of neoadjuvant nab-paclitaxel plus cyclophosphamide (CPA) plus trastuzumab (AbraC-HER) in patients with early HER2-positive breast cancer. Patients and Methods: This was a single-arm, open-label, single center prospective phase II study. The primary endpoint was pathological complete response rate (pCR rate). The secondary endpoints were clinical antitumor efficacy and the frequency and severity of adverse events. Results: Fifty-nine patients were enrolled in this study. pCR (ypT0/is ypN0) was achieved in 29 patients (49%). The overall response rate was 88.1% (52/59) in all patients. Dose reductions because of adverse events occurred in 3 patients (5.1%) and relative dose intensity was 98%. Compared to Abra-HER, AbraCHER induced fewer adverse effects. Conclusion: Treatment with nab-paclitaxel plus CPA plus trastuzumab was tolerable and effective with a high pCR rate. This AbraC-HER neoadjuvant therapy may be a feasible new treatment option for patients with early HER2-positive breast cancer.
引用
收藏
页码：3899 / 3904
页数：6
相关论文
共 50 条
  • [21] IMPRESSIVE OBJECTIVE RESPONSE TO NAB-PACLITAXEL PLUS TRASTUZUMAB AS FIFTH LINE THERAPY IN AELDERLY HER2-POSITIVE-BREAST CANCER PATIENT
    Valerio, Maria Rosaria
    Ancona, Chiara
    Marchese, Antonella
    Cipolla, Calogero
    Graceffa, Giuseppa
    Gebbia, Vittorio
    ACTA MEDICA MEDITERRANEA, 2020, 36 (05): : 3041 - 3045
  • [22] Phase 2 study of neoadjuvant anthracycline followed by nab-paclitaxel and trastuzumab
    Iwamoto, M.
    Tanaka, S.
    Kimura, K.
    Matsunami, N.
    Morishima, H.
    Yoshidome, K.
    Nomura, T.
    Morimoto, T.
    Yamamoto, D.
    Tsubota, Y.
    BREAST, 2015, 24 : S94 - S94
  • [23] Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer
    Yardley, Denise A.
    Raefsky, Eric
    Castillo, Raul
    Lahiry, Anup
    LoCicero, Richard
    Thompson, Dana
    Shastry, Mythili
    Burris, Howard A., III
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2011, 11 (05) : 297 - 305
  • [24] Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer
    Snider, Jessica N.
    Young, Robyn R.
    Schwartzberg, Lee Steven
    Allen, Jeffrey Warren
    Javed, Yasir Ahmed
    Jahanzeb, Mohammad
    Sachdev, Jasgit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A singlearm, open-label, phase II study
    Wang, C.
    Liu, Z.
    Chen, X.
    Qiao, J.
    Li, L.
    Lu, Z.
    Sun, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S436 - S436
  • [26] Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+breast cancer: A BrUOG study
    Sinclair, Natalie Faye
    Sakr, Bachir Joseph
    Abu-Khalaf, Maysa M.
    Somlo, George
    Black, Robert C.
    Chung, Gina G.
    Rizack, Tina
    Strenger, Rochelle
    Fenton, Mary Anne
    DiGiovanna, Michael
    Constantinou, Maria
    Lannin, Donald R.
    Legare, Robert Duffy
    Chagpar, Anees B.
    Sambandam, Sundaresan T.
    Bossuyt, Veerie
    Rosati, Kayla
    Harris, Lyndsay
    Sikov, William M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Investigation of paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab in HER2-positive breast cancer
    Zhang, G-L
    Ba, C-X
    Liu, A-Y
    Ren, D-Q
    Li, H.
    Zhu, J-J
    Fan, J-N
    Zhang, P-L
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 899 - 902
  • [28] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
  • [29] Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases
    Ricciardi, Giuseppina Rosaria Rita
    Russo, Alessandro
    Franchina, Tindara
    Ferraro, Giuseppa
    Adamo, Vincenzo
    ONCOTARGETS AND THERAPY, 2015, 8 : 289 - 294
  • [30] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Chen, W.
    Savoie, J.
    Fornier, M.
    Krop, I. E.
    Winer, E. P.
    Bunnell, C.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
12345